龙血竭抗癌成分的虚拟筛选及体外抗癌活性检测验证

Translated title of the contribution: Virtual Screening of Anticancer Components of Dragon’s Blood and Validating of Anticancer Activity in Vitro

Fang Liu, Rongji Dai*, Fang Lü, Yulin Deng

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

To study anticancer compounds of dragon’s blood, taking HER2 as the target protein receptor, 149 known compounds were virtually screened based on computer-aided screening technology. The potential active components were tested for the effects on HER2 activity in vitro and the anticancer activity on human breast cancer cell SK-BR-3. The results show that the molecular docking model of the HER2 target protein possesses stronger enrichment ability for active molecules. The molecules that can effectively dock with HER2 and have anticancer potential are mainly dihydrochalcones, flavanes, steroids and stilbenes. Among them, four can bind to extracellular and intracellular domain of HER2, and three can bind to intracellular domain of HER2, they all have significant inhibitory effects on HER2 in vitro. Trans-3-methoxy-4',5-dihydroxystilbene and trans-3,4',5-trihydroxystilbene show significant anticancer effects on SK-Br-3 in vitro and can inhibit cancer cell proliferation, change cell cycle, and cause SK-Br-3 very significant apoptosis, which provide a basis data for the development of dragon's blood anticancer drugs.

Translated title of the contributionVirtual Screening of Anticancer Components of Dragon’s Blood and Validating of Anticancer Activity in Vitro
Original languageChinese (Traditional)
Pages (from-to)429-438
Number of pages10
JournalBeijing Ligong Daxue Xuebao/Transaction of Beijing Institute of Technology
Volume43
Issue number4
DOIs
Publication statusPublished - Apr 2023

Fingerprint

Dive into the research topics of 'Virtual Screening of Anticancer Components of Dragon’s Blood and Validating of Anticancer Activity in Vitro'. Together they form a unique fingerprint.

Cite this